A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.
Eyal C. Attar
No relevant relationships to disclose
Jeffrey L. Johnson
No relevant relationships to disclose
Philip C. Amrein
No relevant relationships to disclose
Gerard Lozanski
No relevant relationships to disclose
Martha Wadleigh
No relevant relationships to disclose
Daniel J. DeAngelo
No relevant relationships to disclose
Jonathan E. Kolitz
No relevant relationships to disclose
Bayard L. Powell
No relevant relationships to disclose
Peter Michael Voorhees
No relevant relationships to disclose
Eunice S. Wang
No relevant relationships to disclose
William G. Blum
No relevant relationships to disclose
Guido Marcucci
No relevant relationships to disclose
Clara D. Bloomfield
No relevant relationships to disclose
Barry K Moser
No relevant relationships to disclose
Richard M. Stone
No relevant relationships to disclose
Richard A. Larson
No relevant relationships to disclose